Medcaw Investments Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Medcaw Investments's earnings have been declining at an average annual rate of -218%, while the Capital Markets industry saw earnings growing at 16.3% annually.
Belangrijke informatie
-218.0%
Groei van de winst
-197.9%
Groei van de winst per aandeel
| Capital Markets Groei van de industrie | 16.3% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -32.9% |
| Nettomarge | n/a |
| Laatste winstupdate | 31 Dec 2022 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Medcaw Investments geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 22 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: MCI is currently unprofitable.
Groeiende winstmarge: MCI is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: Unable to establish if MCI's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Versnelling van de groei: Unable to compare MCI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: MCI is unprofitable, making it difficult to compare its past year earnings growth to the Capital Markets industry (-5.9%).
Rendement op eigen vermogen
Hoge ROE: MCI has a negative Return on Equity (-32.86%), as it is currently unprofitable.